| Name | Title | Contact Details |
|---|---|---|
Vinay Bhupathy |
General Counsel | Profile |
Inscripta is a gene-editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity.
Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman`s Lab at Stanford University, which demonstrated complete cures in numerous cancer models.
Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
Network Biosystems, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.